on Biophytis (EPA:ALBPS)
Biophytis Enters Exclusive Negotiations for BIO101 in China
Biophytis, a clinical-stage biotechnology firm, has entered exclusive negotiations with a top Chinese pharmaceutical company to license BIO101. This molecule targets viral respiratory infections, sarcopenia, and obesity. The Chinese partner excels in innovative technology and has access to China’s $190 billion pharmaceutical market.
The collaboration reflects Biophytis's strategy, building on its agreement with Blanver in LATAM. The potential impact in China is substantial, with obesity and sarcopenia affecting millions. This partnership aims to advance BIO101’s development and reach numerous patients.
The move is seen as a significant step for Biophytis to expand its presence internationally and enhance its market strategy through strategic partnerships.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news